[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,75,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100606937","impact-of-uterine-and-ovarian-vessel-occlusion-on-blood-loss-in-high-burden-minimally-invasive-myomectomy-100606937",false,"NCT07182045","Impact of Uterine and Ovarian Vessel Occlusion on Blood Loss in High Burden Minimally Invasive Myomectomy.","Myo-Bleed","Inclusion Criteria:\n\n* Patient undergoing minimally invasive myomectomy with either a single intramural or Submucosal fibroid =\u002F\\>5cm or\n* Patients undergoing minimally invasive Myomectomy with =\u002F\\> 5 fibroids\n\nExclusion Criteria:\n\n* Pregnancy,\n* Age \\\u003C18yo,\n* Patients undergoing concomitant surgery such as endometriosis surgery,\n* Suspected malignancy",true,"FEMALE","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study hypothesizes that temporary bilateral uterine and utero-ovarian artery occlusion with laparoscopic clamps at time of minimally invasive myomectomy will lead to a decreased blood loss at time of myomectomy compared to minimally invasive myomectomy without temporary occlusion.",[27,28],"Myoma","Surgery",[30,31],"myoma","blood loss","RECRUITING","2026-05-12",{"date":35,"type":36},"2026-05-14","ACTUAL",{"date":38,"type":36},"2025-09-18",{"date":40,"type":21},"2029-09-30",{"name":42,"class":43},"The University of Texas Health Science Center, Houston","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100491739","prevention-of-intra-uterine-adhesions-following-laparoscopic-and-laparotomic-myomectomy-100491739","NCT05683041","Prevention of Intra-uterine Adhesions Following Laparoscopic and Laparotomic Myomectomy","PALLM","Inclusion Criteria:\n\n* age between 18 and 45 years.\n* intramurale and\u002For subserosal myoma (FIGO 3-6), and\u002For hybrid myoma (with a connection to the endometrium and serosa (FIGO 2-5), who are scheduled for laparoscopic \u002F laparotomic myomectomy.\n* absence of intra-uterine adhesions on preoperative diagnostic hysteroscopy\n\nExclusion Criteria:\n\n* pregnancy.\n* laparoscopic or laparotomic myomectomy in combination with an operative hysteroscopy.\n* presence of endometritis.\n* other antiadhesion methods","45 Years",{"count":54,"type":21},30,[24],"Clinical study on the prevention of intrauterine adhesions after laparoscopic or laparotomic myomectomy.\n\nMyomas are common in women of reproductive age and myomectomy can lead to intra-uterine adhesions, which can be detrimental to fertility. This study investigates whether the use of an intrauterine gel can prevent the development of these adhesions.",[27],[59,60,61,62,63,64,65],"Postoperative adhesions","Intrauterine adhesions","Myomectomy","Laparoscopic myomectomy","Laparotomic myomectomy","Adhesion prevention","Antiadhesion method","2025-01-22",{"date":68,"type":36},"2025-01-27",{"date":70,"type":36},"2023-02-22",{"date":72,"type":21},"2028-01",{"name":74,"class":43},"University Hospital, Ghent",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":52,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100452340","the-effect-of-intracapsular-injection-of-terlipressin-versus-carbitocin-on-hemoglobin-and-blood-loss-during-laparoscopic-myomectomy-operations-100452340","NCT05170230","The Effect of Intracapsular Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations","The Effect of Intracapsular Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations: Double Blinded Randomized Placebo-Controlled Trial","Inclusion Criteria\n\n1. Women aged 16-45 years\n2. Appropriate medical status for laparoscopic surgery (largest myoma ≤15 cm)\n3. Baseline hemoglobin ≥9 g\u002Fdl\n4. No contra-indications to the use of glyopressin or carbitocin\n5. Myoma-related symptoms, such as pelvic pressure or pain, menorrhagia, or infertility\n6. Not pregnant at the time of presentation (i.e., negative urine pregnancy test or last menstrual period within the last 4 weeks)\n\nExclusion Criteria:\n\n1. Previous myomectomy\n2. History of bleeding disorders\n3. Concurrent anticoagulation therapy\n4. History of Uncontrolled ischaemic heart disease\n5. Any pelvic abnormalities requiring concomitant surgery\n6. Treatment with a GnRH agonist or ulipristal acetate within three months preceding surgery\n7. Inability to understand and provide written informed consent","16 Years",{"count":84,"type":21},99,[24],"Our study aims to evaluate the efficacy of intracapsular injection of Terlipressin versus Carbetocin injection on hemoglobin level in women undergoing abdominal laparoscopic myomectomy. Moreover, to evaluate their efficacy in decreasing blood loss on operative time and to describe the injection sequelae for the same population. This clinical study will be conducted in compliance with the clinical study protocol and applicable regulatory requirements.",[27],"2024-06-24",{"date":90,"type":36},"2024-06-25",{"date":92,"type":36},"2022-02-27",{"date":94,"type":21},"2026-06-30",{"name":96,"class":43},"Wael Elbanna Clinic",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":44},"100459739","the-effect-of-intramyometrial-injection-of-terlipressin-versus-carbitocin-on-hemoglobin-and-blood-loss-during-open-myomectomy-operations-without-using-haemostatic-tourniquets-100459739","NCT05266534","The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets","The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets.","myomectomy","Inclusion Criteri\n\n* Women aged 16-45 yearsAppropriate medical status for open surgery (Largest Myoma size from 4 cm up to 20 cm)\n* Baseline hemoglobin ≥9 g\u002Fdl\n* No contra-indications to the use of glyopressin or carbitocin\n* Myoma-related symptoms, such as pelvic pressure or pain,menorrhagia, or infertility\n* Not pregnant at the time of presentation (i.e., negative urine pregnancy test or last menstrual period within the last 4 weeks)\n\nExclusion Criteria\n\n* Open myomectomy using mechanical tourniquet\n* Previous myomectomy\n* History of bleeding disorders\n* Concurrent anticoagulation therapy\n* History of Uncontrolled ischaemic heart disease\n* Any pelvic abnormalities requiring concomitant surgery\n* Treatment with a GnRH agonist or ulipristal acetate within three months preceding surgery\n* Inability to understand and provide written informed consent","40 Years",{"count":107,"type":21},162,[24],"For gynecologists, reaching a conclusion about the efficacy of intramyometrial Terlipressin injection versus intramyometrial Carbetocin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy that would influence the clinical decision and best practice. Besides enriching the clinical evidence in open myomectomy without using haemostatic tourniquets. For society, our conclusion and recommendation shall maximize the benefits and managing the benefits of the technique used. Moreover, providing more information for women undergoing open myomectomy without using haemostatic tourniquets.",[27],"2022-02-23",{"date":113,"type":36},"2022-03-04",{"date":115,"type":36},"2021-12-30",{"date":117,"type":21},"2026-12-30",{"name":96,"class":43}]